A Randomized, Open Label, 2-Period, 2-Treatment, Cross-over Phase 1 Study to Evaluate the Bio-equivalence of Single Oral Dose of TAK-536 Pediatric Formulation and TAK-536 Commercial Formulation in Healthy Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Azilsartan (Primary)
- Indications Essential hypertension; Hypertension
- Focus Pharmacokinetics
- Sponsors Takeda
- 29 Jun 2017 Planned number of patients changed from 14 to 28.
- 29 Jun 2017 Status changed from recruiting to completed.
- 06 Feb 2017 New trial record